Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations: 2020-2021

Historic Cash from Discontinued Operations for Agios Pharmaceuticals (AGIO) over the last 2 years, with Dec 2021 value amounting to -$4.1 million.

  • Agios Pharmaceuticals' Cash from Discontinued Operations fell 335.48% to -$4.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$93.2 million, marking a year-over-year decrease of 99.15%. This contributed to the annual value of -$93.2 million for FY2021, which is 99.15% down from last year.
  • As of Q4 2021, Agios Pharmaceuticals' Cash from Discontinued Operations stood at -$4.1 million, which was up 60.24% from -$10.3 million recorded in Q3 2021.
  • In the past 5 years, Agios Pharmaceuticals' Cash from Discontinued Operations ranged from a high of $1.7 million in Q4 2020 and a low of -$48.3 million during Q2 2021.
  • Moreover, its 2-year median value for Cash from Discontinued Operations was -$11.0 million (2020), whereas its average is -$17.5 million.
  • Over the last 5 years, Agios Pharmaceuticals' Cash from Discontinued Operations had its largest YoY gain of 11.00% in 2021, and its largest YoY loss of 364.92% in 2021.
  • Over the past 2 years, Agios Pharmaceuticals' Cash from Discontinued Operations (Quarterly) stood at $1.7 million in 2020, then crashed by 335.48% to -$4.1 million in 2021.
  • Its last three reported values are -$4.1 million in Q4 2021, -$10.3 million for Q3 2021, and -$48.3 million during Q2 2021.